jueves, 14 de febrero de 2019

For BeiGene, Bristol-Celgene deal is poised to have big ripple effects

For BeiGene, Bristol-Celgene deal is poised to have big ripple effects



STAT Plus: For a Chinese cancer drug developer, Bristol-Celgene deal is poised to have big ripple effects

By REBECCA ROBBINS


IMAGINECHINA VIA AP
Like other leaders of China’s biotech sector, BeiGene is positioning itself as a global company, with ambitions to export drugs to the rest of the world.

No hay comentarios: